PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300
12 months from date of receipt / reconstitution, -20 °C as supplied
| 应用 | 稀释度 | 推荐种属 |
|---|---|---|
| WB | 1:1000 | Ms, Rt |
SLAMF8, also known as B-lymphocyte activator macrophage expressed (BLAME) or CD353, is a single-pass type I membrane protein belonging to the SLAM (Signaling Lymphocyte Activation Molecule) family. It is characterized by the presence of Ig-like domains and is primarily expressed in immune-related tissues such as the lymph node, spleen, and thymus. SLAMF8 has been identified as a potential new immune checkpoint molecule, with its high expression associated with poor prognosis in colorectal cancer. This protein is involved in immune regulation and may play a role in various immune responses, including those related to inflammation and autoimmune diseases.
WB result of SLAMF8 Recombinant Rabbit mAb
Primary antibody: SLAMF8 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: mouse lung lysate 20 µg
Lane 2: mouse thymus lysate 20 µg
Lane 3: mouse spleen lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 32 kDa
Observed MW: 25 kDa
WB result of SLAMF8 Recombinant Rabbit mAb
Primary antibody: SLAMF8 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: rat lung lysate 20 µg
Lane 2: rat thymus lysate 20 µg
Lane 3: rat spleen lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 32 kDa
Observed MW: 25 kDa
您现在的位置：